Peptide LexiconAll compounds

Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate): The 'Snake Venom' Cosmetic Peptide, as a Molecule

Syn-Ake is the trade name of a small synthetic peptide-like molecule used in anti-wrinkle creams, sold under the INCI name dipeptide diaminobutyroyl benzylamide diacetate. It was designed with waglerin-1, a pit-viper toxin, as a template, but contains no venom. This entry covers the structure, the venom it imitates and the three PubMed records that name it.

Cosmetic ingredientNot a medicineContains no venom

Caroline S · Published 2026-11-17

Length

Three building blocks plus a benzylamide end — as the diacetate salt C23H37N5O7, molecular weight 495.6 (PubChem CID 71465152); the peptide part alone C19H29N5O3, about 375.5 (our calculation)

Sequence

β-Ala-Pro-Dab-NH-benzyl (3-aminopropanoyl-prolyl-2,4-diaminobutanoyl benzylamide; from the PubChem name), as the diacetate

Origin

Synthetic; marketed under the trade name SYN-AKE; designed using waglerin-1 from Wagler's pit viper as a template

Last reviewed

2026-11-17

What is it good for?

It is sold as an anti-wrinkle ingredient said to relax the muscle movements that make expression lines, imitating a viper toxin that blocks nerve-to-muscle signals. The published human evidence is one 2026 study of a serum containing it alongside other actives, with no vehicle-controlled arm described in the abstract, so the ingredient's own effect is not isolated.

Illustration: A small white and deep green molecular model on a white surface.
Illustration

What it is

Syn-Ake is a trade name for a small synthetic molecule used in anti-wrinkle creams. On an ingredient list it appears as dipeptide diaminobutyroyl benzylamide diacetate. PubChem records it as CID 71465152 (read 2026-11-17):

Property Value Source
Building blocks Beta-alanine · proline · 2,4-diaminobutyric acid, ending in a benzylamide PubChem chemical name
Formula (diacetate salt) C23H37N5O7 PubChem CID 71465152
Molecular weight (diacetate) 495.6 PubChem
Formula (without the two acetates) C19H29N5O3, about 375.5 Our calculation
Origin Synthetic —

"Dipeptide" in the name undersells and oversells at once. Reading the PubChem name, the chain has three building blocks, not two — but only proline is one of the twenty standard amino acids in proteins. Beta-alanine and diaminobutyric acid are non-standard, and the end is capped with a benzyl group rather than a normal peptide end (our reading of the name). It is peptide-like rather than a classic peptide.

The venom it imitates

The molecule was designed using waglerin-1 as a template — a toxin of Wagler's pit viper, Tropidolaemus wagleri. A 2017 paper on the toxin's evolution names the connection in its title: the waglerin peptides used in anti-wrinkle skin cream (Debono et al., J Mol Evol, PMID 27864608).

UniProt's record for the precursor (P24335, read 2026-11-17) gives waglerin-1 as 22 amino acids, GGKPDLRPCHPPCHYIPRPKPR, cut from a 24-residue chain. Set the two side by side and the cosmetic is not a fragment of the toxin: it is a three-unit synthetic, about a sixth the length (our comparison). The resemblance claimed is in how it is meant to act, not in its sequence.

Waglerin-1 selectively blocks the epsilon subunit of the muscle nicotinic acetylcholine receptor (UniProt P24335), the receptor that receives the nerve's signal to contract. UniProt adds that in mice it causes rapid collapse and spasms, while rats show no toxic effect on breathing or blood pressure — a reminder that a toxin's action differs by species. The cosmetic idea is that a molecule acting there could soften the repeated small contractions behind expression lines. No study found tonight tested this molecule at that receptor.

What PubMed holds

A search under the trade name and the INCI name on 2026-11-17 returned three records:

Year Journal What was done Isolates Syn-Ake's own effect?
2024 J Biomol Struct Dyn (PMID 37349941) Computer docking against collagen-breaking MMP enzymes and SIRT1; antioxidant, cytotoxicity and Ames mutagenicity tests in the laboratory In vitro only
2026 Int J Cosmet Sci (PMID 41668671) L'Oréal serum with acetyl hexapeptide-8, this peptide, gluconolactone, niacinamide and laminaria extract; skin explants plus clinical studies of 50 and 42 people over 12 weeks No — five actives together
2026 3 Biotech (PMID 42927054) A nanoemulsion containing "peptide acting on neurotransmitters" (title; not read) Not read

The 2026 serum study reports static-wrinkle clinical scores improving by 35% to 69% and dynamic wrinkles by 10% to 13% after 12 weeks (all P < 0.001). Its abstract describes no vehicle or placebo arm in the clinical studies, and the authors are L'Oréal researchers testing their own formula. With five actives in one serum, the result cannot be assigned to any one of them.

For scale: PubMed holds the three records above for this ingredient, while "waglerin" — the toxin it imitates — returns 20 when searched the same way.

Where it stands

Syn-Ake is a cosmetic ingredient, not a drug, and is not listed in Drugs@FDA. The library's Argireline entry covers the other "Botox-like" cosmetic peptide that shared the 2026 serum, and SNAP-8 its longer relative. PeptideGlowJournal's Syn-Ake ingredient page reads the ingredient in finished products; this entry stops at the molecule and its record.

Sources opened 2026-11-17: PubChem CID 71465152; UniProt P24335; Gok et al. 2024 (PMID 37349941); Zhu et al. 2026 (PMID 41668671); Debono et al. 2017 (PMID 27864608, record); 3 Biotech 2026 (PMID 42927054, title); PubMed E-utilities and ClinicalTrials.gov API v2 counts.

What the research shows

Reduces wrinkles

Zhu et al. 2026, Int J Cosmet Sci (PMID 41668671, L'Oréal): serum with acetyl hexapeptide-8, this peptide, gluconolactone, niacinamide and laminaria extract; 50 and 42 participants, 12 weeks; no vehicle-controlled arm in the abstract

Acts like the waglerin toxin on muscle

Supplier design rationale; Debono et al. 2017, J Mol Evol (PMID 27864608) — title: the waglerin peptides 'used in anti-wrinkle skin cream'; no study of this molecule at the receptor was found

Anti-ageing activity in cells

Gok et al. 2024, J Biomol Struct Dyn (PMID 37349941): computer docking against MMP enzymes and SIRT1, antioxidant, cytotoxicity and Ames tests in vitro

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

Regulatory

A cosmetic ingredient, not a drug: Drugs@FDA lists no product containing it (2026-11-17).

Trials

ClinicalTrials.gov: 0 studies for 'syn-ake' (2026-11-17).

Published record

PubMed: 3 records under the trade or INCI name, 2024–2026; 0 tagged as randomised trials (2026-11-17).

Frequently asked questions

What is Syn-Ake?

The trade name of a synthetic anti-wrinkle ingredient, listed on labels as dipeptide diaminobutyroyl benzylamide diacetate. It is a small peptide-like molecule designed to imitate a toxin from Wagler's pit viper.

Does Syn-Ake contain snake venom?

No. It is made in a laboratory. Waglerin-1, the viper toxin it was modelled on, is 22 amino acids long; Syn-Ake is three building blocks and a benzylamide group, so it is not a copy of the toxin, only inspired by it.

How is Syn-Ake supposed to work?

Waglerin-1 blocks the receptor on muscle that receives signals from nerves. The design idea is that a much smaller molecule acting the same way could relax the small muscle movements behind expression lines. No published study tested that mechanism for this ingredient.

Does Syn-Ake work?

The published evidence is thin. The one human study tested a serum with five actives together, so it cannot show what Syn-Ake alone does. The other two records are laboratory and computer studies.

Is Syn-Ake the same as Argireline?

No. Argireline (acetyl hexapeptide-8) is a six-amino-acid peptide with its own entry in this library. Syn-Ake is a different, smaller molecule modelled on a toxin that acts on the muscle receptor. The 2026 serum study contained both.

Is Syn-Ake like Botox?

Only in the marketing idea of reducing muscle movement. Botox is a prescription injection of botulinum toxin. Syn-Ake is a cosmetic cream ingredient with no drug approval and no trial isolating its effect.